Methyl tertiary butyl ether (MTBE) is an additive in some formulations of unleaded gasoline (UG) that enhances octane and reduces carbon monoxide emissions from motor vehicles. MTBE in CD-I mice and UG in B6C3F1 mice increased the incidence of liver tumors selectively in female mice in their chronic bioassays. Both agents were negative in in vitro tests of genotoxicity, and exhibit similar hepatic microsomal cytochrome P450 activity and hepatocyte proliferation after short-term exposure. We previously demonstrated that UG has hepatic tumor-promoting activity in DEN-initiated female B6C3F1 mice. Thus, we hypothesized that MTBE would have hepatic tumor-promoting activity in the same initiation-promotion model system in which UG was a hepatic tumor promoter. Twelve-day-old female B6C3F1 mice were initiated with a single i.p. injection of the mutagen iV-nitrosodiethylamine (DEN) (5 mg DEN/kg, 7.1 ml/kg body weight) or saline. Beginning at 8 weeks of age, mice were exposed to 0 ppm or the hepatocarcinogenic dose of approximately 8000 ppm MTBE. After subchronic exposure, MTBE significantly increased liver weight and hepatic microsomal cytochrome P450 activity without hepatotoxicity or an increase in non-focal hepatocyte DNA synthesis. These are subchronic effects similar to those produced by UG. However, MTBE did not significantly increase the mean size of hepatic foci and volume fraction of the liver occupied by foci as compared to DEN-initiated controls at either 16 or 32 weeks. The lack of tumorpromoting ability of MTBE in DEN-initiated female mouse liver was unexpected and suggests that MTBE does not produce liver tumors through a tumor-promoting mechanism similar to that of UG.
Introduction
Methyl tertiary butyl ether (MTBE*) is an additive in some formulations of unleaded gasoline (UG). Currently, MTBE is used to boost octane or reduce carbon monoxide levels in automobile exhaust in compliance with the Clean Air Act. At least 20% of the UG sold in 1995 contained MTBE at levels ranging from 2 to 15%. In the United States, an estimated 12 million tons or more of MTBE will be used in 1996 (1,2).
•Abbreviations: ALT, alanine aminotransferase; BrdU, monoclonal anti-5-bromo-2'-deoxyuridine; DEN, W-nitrosodiethylamine; DMN-AC, methyl(acetoxymethyl)nitrosamine; EROD, 7-ethoxyresorufin-O-de-ethylase; LI, liver DNA synthesis; MTBE, methyl tertiary butyl ether, PROD, 7-pentoxyresorufin-O-dealkylase; UG, unleaded gasoline.
The major route of exposure is by inhalation to workers during the production and transportation of MTBE, and to the general public during refueling with UG blends that contain MTBE (3, 4) . The health risk to humans of low-dose, intermittent exposure to MTBE and formulations of UG supplemented with MTBE is unknown.
MTBE produced carcinogenic and toxic effects in chronic bioassays similar to those produced by UG (Table I) (5) (6) (7) . Inhalation of the high dose of 8000 ppm (28 800 mg/mm 3 ) MTBE in CD-I mice and F344 rats increased the incidence of kidney tumors in male rats and liver tumors in female mice (6, 7) . The increased incidence of liver tumors in MTBEexposed female mice was accompanied by a decreased incidence of endometrial hyperplasia. The MTBE-induced rodent tumor profile and effects in the mouse uterus after inhalation exposure were similar to those produced by UG vapor after chronic exposure in B6C3F1 mice and F344 rats (8) (Table I) .
Under bioassay conditions in a two-stage initiation-promotion model system, UG increased the size of hepatic foci and volume fraction of the liver occupied by hepatic foci in Nnitrosodiethylamine (DEN)-initiated female B6C3F1 mouse liver (9,10; Table I ). Increased mean focal size and volume fraction of the liver occupied by hepatic foci are parameters associated with hepatic tumor promoters. Thus, UG has been classified as having hepatic tumor-promoting activity. Tumor promotion by UG was only observed at the high exposure level of 2038 ppm and not at lower doses of 67 and 292 ppm. Since only the high dose induced hepatic tumors, the tumorpromoting ability of UG is believed to play a central role in UG-induced hepatocarcinogenicity. UG elicits a number of short-term hepatic effects in female B6C3F1 mice believed to be relevant to its tumor-promoting activity: hepatomegaly, increased hepatic microsomal cytochrome P450 activity and transient increase in hepatocyte proliferation in the absence of hepatotoxicity (9, 10) . After short-term exposure under bioassay conditions, MTBE vapor also increased liver weight, hepatic microsomal P450 activity and hepatic DNA synthesis in female B6C3F1 mice (11). Therefore, MTBE elicited short-term hepatic effects similar to those produced by the hepatic tumor promoter UG.
These data, along with the lack of genotoxicity of UG and MTBE in short-term assays (12) (13) (14) (15) (16) , suggest that MTBE and UG may be hepatocarcinogenic through similar non-genotoxic mechanisms (Table I ). An understanding of the mechanisms of action of MTBE and UG is necessary to predict human health risks to formulations of UG containing MTBE. Thus, the objective of our studies was to compare the biological effects of MTBE on the mouse liver to those UG-induced responses that have been characterized. Whereas the MTBE chronic bioassay was done in CD-I mice, all other experiments with UG and MTBE were done in B6C3F1 mice. Thus, we initially compared the short-term effects of MTBE under bioassay conditions in CD-I mice with those produced in B6C3F1 mice. Here, we demonstrated that MTBE generally Chun et al. 1993 ). Short-term effects were determined under exposure conditions similar to those of the bioassay (6 h/day, 5 days/week) in female B6C3F1 mice exposed for 3 or 21 days (11). In the tumor promotion study, B6C3F1 mice were exposed under conditions similar to those of the bioassay for 16 weeks (10).
produced short-term hepatic effects in CD-I mice similar to those produced in B6C3F1 mice.
Given the comparable short-term effects in CD-I and B6C3F1 mice, the similarities between UG and MTBE after chronic and short-term exposure, and the known tumor-promoting ability of UG, we hypothesized that MTBE is also a hepatic tumor promoter in DEN-initiated female mouse liver. We conducted an initiation-promotion study in B6C3F1 mice utilizing the same model system in which UG was shown to be a hepatic tumor promoter. In spite of all the chronic and short-term in vivo and in vitro similarities between MTBE and UG, we report here that MTBE, unlike UG, did not significantly increase mean size of hepatic foci or increase volume fraction of the liver occupied by hepatic foci in DEN-initiated female mouse liver.
Materials and methods

Chemicals
High-purity MTBE (CAS no. 1624-04-4, Lot no. SC940225T-59-1) (>99.95% pure) was provided by ARCO Petroleum Co. (Newton Square, PA). Monoclonal anti-5-bromo-2'-deoxyuridine (BrdU) for immunohistochemistry was purchased from Becton-Dickson (Mountain View, CA). Isoflurane was obtained from Anaquest (Guayama, Puerto Rico). All other chemicals were obtained from Sigma Chemical Co. (St Louis, MO). Animals All experiments were conducted under National Institutes of Health (NIH) guidelines for the care and use of laboratory animals, and approved by the Institutional Animal Care and Use Committee, Chemical Industry Institute of Toxicology (CUT). For the short-term experiments, female B6C3F1 and CD-1 mice were obtained from Charles River Breeding Laboratories (Raleigh, NC). To breed B6C3F1 mice for the tumor promotion study, male C3H/ HeNCrlBR mice and female C57BL/6NCrIBR mice were obtained from Charles River Breeding Laboratories (Raleigh, NC). All mice were quarantined upon arrival for at least 10 days and housed in humidity-and temperaturecontrolled HEPA-filtered rooms in facilities accredited by the American Association of Laboratory Animal Care.
Comparison of short-term effects of MTBE vapor in B6C3F1 and CD-I female mice
Experimental design. A one-factor (treatment), two-level design was used to evaluate the short-term hepatic effects of MTBE under bioassay conditions in CD-I mice to those produced in B6C3F1 mice. Both mouse strain and number of days exposed were blocked in this experiment. The outcomes used to evaluate the effect of MTBE exposure were liver weight, microsomal P450 activity, hepatotoxicity as measured by liver enzymes and liver DNA synthesis (LI) as measured by the incorporation of BrdU.
Animal treatments. Groups of six female B6C3F1 and CD-I mice were housed individually in hanging stainless steel cages contained in 1-m 3 stainless steel and glass, whole-body inhalation chambers. Two 1-m 3 chambers were in one 8-m room. Beginning at 7-8 weeks of age, mice were exposed to HEPAfiltered, particulate-free control air that contained 0 ppm MTBE as monitored by gas chromatography analysis or a target concentration of 8000 ppm MTBE 6 h/day, 5 days/week (6) . A mean duration-adjusted concentration of 7814 ppm MTBE was generated by the flow of liquid MTBE into a stainless-steel J-tube containing glass beads. The vaporized MTBE was carried by a stream of nitrogen and mixed with HEPA-filtered air before delivery to the MTBE chambers. Chamber concentrations were determined at least hourly using an average molecular weight of 88 g/mol and density of 0.740 g/ml for MTBE. Exposures were carried out during the light hours (08: 30-14:30) .
Filtered tap water and NIH-07 pelleted diet (Ziegler Bros., Gardners, PA) were available ad libitum, except that feed was not available during the 6-h inhalation exposure periods. The chambers were maintained at 68-76°F and 40-60% humidity, and on a 12-h light:dark cycle with the light period extending from 07:00-19:00. Mice were randomized by weight before the start of experimentation so that mean starting weights of the groups were not significantly different prior to exposure. Clinical observations and body weights were determined at least once weekly.
Initiation-promotion experiment
Experimental design. A one-factor (treatment) two-level design was used to evaluate the hepatic tumor-promoting ability and subchronic hepatic responses of MTBE. In addition to the endpoints evaluated in the short-term study described above, number and size of hepatic foci, volume fraction of the liver occupied by foci, number of macroscopic hepatic lesions, and number and percentage of hepatocellular adenomas and carcinomas were determined.
Animal treatments. B6C3F1 mice were bred as previously described (9) . Twelve-day-old female B6C3F1 mice were initiated with a single i.p. injection of DEN (5 mg DEN/kg, 7.1 ml/kg body weight) or saline in accordance with the infant mouse initiation-promotion model system (9, 10, 17) . Beginning at 8 weeks of age, groups of 12 DEN-initiated and saline-injected mice were exposed to control air or a target concentration of 8000 ppm MTBE for 16 or 32 weeks under the same conditions as those previously described in the short-term experiment. Mice were randomized by weight before treatment by computer-generated numerical randomization tables.
Necropsy. In both the short-term and tumor promotion studies, mice were weighed and anesthetized with isoflurane approximately 18 h after the last exposure. The thoracic cavity was opened and blood withdrawn via cardiac puncture with a 21-gauge needle. Mice were killed by exsanguination. Blood was allowed to clot for a minimum of 30 min before centrifugation to obtain serum for alanine aminotransferase (ALT). Serum ALT activity was assayed immediately after necropsy using a commercial kit (no. 44924) from Roche Diagnostics (Montclair, NJ). The liver was removed, rinsed in saline and blotted dry. After weighing, the liver was separated by lobes, sectioned into 2-mm strips, and examined for the presence of macroscopically visible lesions. All observed macroscopic lesions were described, mapped, and quantitated by size (< 2, 2 < X < 4, or > 4 mm). Up to six representative tumors per mouse were microscopically examined. Liver sections from the left, median right and anterior lobes along with a section of duodenum were fixed in 10% phosphate-buffered formalin. After 48 h, formalin was replaced with 70% ethanol. Liver sections were embedded in paraffin and sectioned at 5 |im for the hepatic data endpoints.
Microsome preparation. At necropsy, livers from three randomly chosen mice within the same group from the tumor promotion experiment were flushed and microsomes were individually prepared as previously described (18) . Microsomes were stored at -80°C.
Microsomal assays. Hepatic cytochrome P450 content and 7-pentoxyrcsonifin-0-dealkylase (PROD) and 7-ethoxyresorufin-O-deethylase (EROD) activity from at least three microsomal samples from individual mice from each group were determined as previously described (9) . PROD is a marker enzyme of the cytochrome P450 2B1/2 family and EROD is a marker enzyme of the P450 1A1/2 family. Cytochrome P450 content was determined in COytreated microsomes utilizing an extinction coefficient of 104 mM/cm (19) . The fluorometric method of Lubet was used to determine PROD and EROD activity (20). The rate of increase in fluorescence was converted to pmol resorufin per minute by means of a standard curve generated from the fluorescence of known amounts of resorufin. The assays were linear with time.
Microsomal protein was assayed with Coomassie-Plus Protein Assay Reagent (Pierce, Rockford, IL) using bovine serum albumin (Pierce) as a standard.
Hepatocyte proliferation. At least eight mice per group from the tumor promotion study were implanted 3j days before necropsy at approximately 14:00, with 7-day osmotic pumps (Alzet model 2001, 1.06 \lVh, Alza Corporation, Palo Alto, CA) containing 16 mg BrdU (Sigma Chemical Co., CAS no. 59-14-3, > 99% pure)/ral phosphate buffered saline (pH 7.2). Coded paraffin sections of liver were stained for BrdU, and non-focal and focal hepatocyte proliferation was determined as previously described by light microscopy with the investigator blind as to animal treatment (9, 21) . The minimal total number of non-focal hepatocellular nuclei counted was 1000.
For focal hepatic labeling index (LI), serial sections 5 |im in thickness were cut. One liver section was stained with H&E; the next section was immunohistochemically stained for BrdU. Foci were located on H&E-stained sections, and the corresponding focus was identified on BrdU-stained slides. All hepatocytes within 40 DEN/Ct and 33 DEN/MTBE foci were counted, and scored as labeled or unlabeled.
Focal and non-focal hepatic LI were calculated by dividing the number of labeled nuclei by the total number of hepatocellular nuclei counted and multiplying by 100. The mean ± SD from each group was calculated after tissue slides were decoded.
Quantitation of altered hepatic foci.
A transection of the same area of livers (5 |im) from all mice were stained with hematoxylin and eosin (H&E). The total area of all three liver sections was determined with an Image-1 image processing system (Universal Imaging Corp., West Chester, PA). With the experimenter blind to the treatment group, hepatic foci > 10 cells in size were located and phenotypically classified as basophilic or acidophilic according to published criteria (22) . The area of an individual transection of those hepatic foci was used to calculate the number per cm 3 , number per liver, mean volume of foci and volume fraction of the liver occupied by foci according to the sterological method of (23) . At 32 weeks for liver sections with hepatocellular adenomas and carcinomas, the area occupied by adenomas and carcinomas was subtracted from the total area of the three liver sections to determine the number of foci per cm 3 , number of foci per liver, mean volume of foci and volume fraction of the liver occupied by foci.
Statistical analysis
Each group consisted of 5-6 animals in the short-term experiment or 10-12 animals in the tumor promotion study. Mean ± SD was determined for each of the following quantitative endpoints: body and liver weight (g), relative liver weight (organ-to-body weight ratio expressed as %), serum ALT (IU/1), P450 content (nmol/mg microsomal protein), PROD activity (pmol/min/mg microsomal protein), EROD activity (pmol/min/mg microsomal protein), hepatic LI (%), number of macroscopic lesions by size categories, number of hepatic foci (per cm 3 or liver), volume fraction of liver occupied by hepatic foci (%) and mean hepatic volume (mm 3 ). The MTBE treatment group means were compared to control means by the unpaired, two-sided Student's t test. For focal LI, mean animal LI were utilized to determine group mean LI. The hepatic LI, mean volume of foci and volume fraction of the liver data were transformed, since they were not normally distributed. LI index was transformed by arcsin of the square root of LI, and foci size and volume fraction were log-transformed before testing for significance by Student's ( test. A multivariate test was utilized to evaluate the percentage foci, adenomas, and carcinomas induced in DEN-initiated livers. A significance level of 0.05 was used for all analyses.
Results
Short-term hepatic effects of MTBE in B6C3F1 and CD-I mice
Female B6C3F1 mice and CD-I mice were exposed to MTBE for 3 or 21 days. All daily mean analytical concentrations were within 10% of the target exposure concentration of 8000 ppm MTBE. The duration-adjusted mean exposure concentration of MTBE was 7814 ± 81 ppm. Abnormal gait, hypoactivity, decreased muscle tone and increased lacrimation were observed during exposure and immediately after termination of exposure in MTBE-exposed mice. These observations were similar to those seen in the cancer bioassay (6) . After termination of each daily exposure, mice recovered quickly.
Three days of exposure to MTBE did not significantly alter body weight in either strain of mice as compared to their appropriate controls (Table IT) . MTBE produced a significant decrease of body weight in female CD-I mice, but not in B6C3F1 mice after 21 days. As compared to their appropriate controls, liver (data not shown) and liver-to-body weight ratios significantly increased after MTBE exposure in both strains of mice at both time points (Table II) . Based upon histopathological examination of H&E-stained liver sections, MTBE produced slight centrilobular hypertrophy in both B6C3F1 mice and CD-I mice at 3 days as compared to their respective controls. At 21 days, there were no microscopic differences between livers exposed to MTBE and controls, and no indication of hepatotoxicity or necrosis was detectable on H&E-stained liver sections in either strain. Consistently, there was no increase in mean serum ALT activity, an enzyme indicative of liver damage, in MTBE-exposed mice as compared to controls at either time point (data not shown).
MTBE significantly increased total microsomal cytochrome P450 content after 3 days in CD-I mice, and after 21 days in B6C3F1 and CD-I mice as compared to controls (Table II) . MTBE significantly increased PROD and EROD activities at 3 and 21 days in B6C3F1 mice and CD-I mice (Table II) .
MTBE significantly increased the hepatic LI at 3 days as compared to controls in both strains of mice (2.8-and 3.1-fold in B6C3F1 and CD-I mice, respectively). At 21 days, MTBE caused a slight, but significantly decreased hepatic LI in B6C3F1 mice and increased hepatic LI in CD-I mice (Table II) .
Tumor promotion study in B6C3F1 mice Exposure conditions and survivability after 16 or 32 weeks.
The mean exposure concentrations and standard deviation were 7924 ± 135 ppm (99.1% of target concentration) at 16 weeks and 7919 ± 198 ppm (99.0% of target concentration) at 32 weeks (data not shown). These duration-adjusted exposure levels closely approximated the target exposure concentration of 8000 ppm MTBE. Clinical observations in B6C3F1 mice after subchronic MTBE exposure were similar to those seen after 3 or 21 days of MTBE exposure. However, the severity of muscular weakness and time to recovery generally decreased with increased duration of exposure to MTBE. At 16 weeks, survivability was 100% (24/24) for controls and 92% (22/24) for MTBE-exposed mice. At 32 weeks, survivability was 96% (23/24) for controls and 88% (21/24) for MTBE-exposed mice (data not shown). All deaths in MTBE-exposed mice were accompanied by weight loss, which was attributed to MTBE exposure.
Hepatic non-neoplastic observations. Treatment with DEN did not significantly alter body weight relative to saline-treated controls at any time point examined. MTBE exposure significantly decreased body weight at both 16 and 32 weeks in salinetreated and DEN-initiated female B6C3F1 mice, as compared to HEPA-filtered, air-exposed control mice (Table in) . The loss in body weight in MTBE-exposed mice ranged from a 15% decrease in DEN/MTBE mice at 16 weeks to a 25% decrease in DEN/MTBE mice at 32 weeks. A significant increase in liver weight as compared to controls was observed after MTBE exposure at both time points in saline-treated mice and at 16 weeks in DEN-initiated mice. After 16 weeks of exposure to MTBE, liver weights significantly increased 13 and 19% in saline-treated and DEN-initiated mice, respectively, "Beginning at 8 weeks of age, mice were exposed to Hepa-filtered control air or 7814 ± 81 ppm MTBE for 3 or 21 days, 6 h/day, 5 days/week. ''Liver weight/body weight.
•fylean ± SD of at least five mice. d Mean ± SD of three microsomal samples. c Osmotic pumps containing 16 mg BrdU/ml were implanted 3j days before necropsy. At least 2000 hepatic nuclei were evaluated in the left lobe. LI is expressed as percentage labeled nuclei that incorporated BrdU as a function of total number of hepatic nuclei counted. *Significantly different from control (P < 0.05). •Significantly different from control (P < 0.05).
as compared to controls (Table III) . After 32 weeks of exposure to MTBE, liver weights increased 18% in saline-treated and decreased 8% in DEN-initiated mice (Table III) . Relative liver weight significantly increased with MTBE exposure in both saline-treated and DEN-initiated mice after 16 and 32 weeks (Table IE) . This increased relative liver weight was due in part to decreased body weight after MTBE exposure. Examination of H&E-stained livers by light microscopy indicated that DEN did not produce detectable non-neoplastic histopathological changes. Exposure to MTBE in both salinetreated and DEN-initiated livers showed mild centrilobular to mid-zonal hypertrophy extending out one-half to two-thirds of the lobule as compared to non-MTBE-exposed mice. No indications of cytotoxicity or hepatic necrosis were detectable on H&E-stained liver sections after MTBE exposure. Likewise, serum ALT, an enzyme indicative of liver damage, was similar in MTBE-exposed mice and controls at both time points (data not shown).
Hepatic neoplastic observations. At necropsy at 16 and 32
weeks, all livers were examined for macroscopic lesions. Pale white, well-circumscribed masses ranging in size from 1 to 12 mm were observed in DEN-initiated livers. At 16 weeks, only two macroscopic hepatic lesions were visible in 1 of 12 mice in the DEN/control group (data not shown). Both lesions measured <2 mm in diameter. No macroscopic lesions were observed at 16 weeks in DEN/MTBE mice. At 32 weeks, however, all DEN/MTBE and DEN/control mice exhibited pale white macroscopic lesions. At 32 weeks, MTBE exposure significantly decreased the mean number of macroscopic lesions in all three size categories (Figure 1) . At 32 weeks, MTBE also significantly decreased the average total number of macroscopic lesions per tumor-bearing mouse from 38.0 in DEN/control mice to 13.8 in DEN/MTBE mice.
Hepatic microscopic observations. Identification and the phenotype of individual hepatic foci were determined by microscopic examination of H&E-stained liver sections. At 16 weeks, no hepatic foci were found in any saline-treated mice. At 32 weeks in the liver sections we microscopically examined, one saline/control liver had a basophilic focus and one saline/ MTBE liver had an acidophilic focus.
At 16 weeks, MTBE did not significantly alter the number or size of hepatic foci or the volume fraction of the liver occupied by hepatic foci as compared to DEN/control (Table  IV) . MTBE exposure for 32 weeks did not significantly alter the number of hepatic foci; however, it did significantly decrease the mean volume fraction of the liver occupied by hepatic foci (76%) and mean volume of foci (74% ; Table IV) . Thus, at 32 weeks, the volume fraction and mean size of the foci in DEN/MTBE livers correlated with the significant decrease in the mean number of macroscopic lesions.
In H&E-stained livers, over 98% of hepatic foci in DEN/ control mice and 92% in DEN/MTBE were classified as basophilic foci at both 16 and 32 weeks. Basophilic foci were round or oval and well defined with the focal hepatocytes < 2 mm >4 mm 10-, DEN/Ct DEN/MTBE Treatment groups Fig. 1 . Effect of MTBE exposure for 32 weeks on mean number and size of hepatic macroscopic lesions. Twelve-day-old female B6C3F1 mice were initiated with a single i.p. injection of DEN (5 mg DEN/kg, 7.1 ml/kg body weight) or saline Beginning at 8 weeks of age, groups of 10-12 mice were exposed 6 h/day, 5 days/week to 0 or 7986 ± 107 ppm MTBE for 16 weeks or 7969 ±116 ppm MTBE for 32 weeks. At necropsy, the liver was cut into 2-mm sections and examined for macroscopic lesions. The number of lesions in each of three size classes (« 2, 2 < X « 4, or > 4 mm) was determined for each animal and the mean calculated for each group.
exhibiting increased cytoplasmic basophilia relative to adjacent normal hepatocytes. Hepatocytes within the focus were smaller, and had an increased nuclear-to-cytoplasmic ratio and cytoplasmic vacuolization relative to surrounding nonfocal hepatocytes.
At 16 weeks, one of 88 foci (1.1%) was acidophilic in DEN/control and five foci of 57 were acidophilic (8.8%) in DEN/MTBE liver sections. The five acidophilic foci in the DEN/MTBE group were found in four different mice. At 32 weeks, 17% of DEN/control livers and 70% of DEN/MTBE livers had at least one acidophilic focus; three of 254 foci (1.2%) in DEN/control and 11 of 136 foci (8.1%) in DEN/ MTBE were of the acidophilic phenotype (Figure 2 ). Focal hepatocytes in acidophilic foci were larger than focal hepatocytes in basophilic foci, and generally demonstrated an increased nuclear size and pale pink cytoplasm relative to nonfocal hepatocytes. At 32 weeks, there was no significant difference in mean number or size of acidophilic foci or volume fraction of the liver occupied by acidophilic foci in DEN/MTBE and DEN/control mice (data not shown).
At 16 weeks, no hepatocellular adenomas or carcinomas were found in any mice. At 32 weeks, hepatocellular adenomas and carcinomas were found in DEN/control and DEN/MTBE livers ( Figure 3 ). Representative H&E sections from 88% of DEN/control and 90% of DEN/MTBE mice displayed hepatocellular adenomas (data not shown). Hepatocellular adenomas were composed of well-differentiated hepatocytes resembling cells of foci that formed regular cords one cell in thickness. Adenomas compressed surrounding nonfocal hepatocyte cytoplasm. At 32 weeks, hepatocellular carcinomas were identified in 50% of DEN/control and 40% of DEN/ MTBE livers (data not shown). Hepatocellular carcinomas displayed a trabecular pattern with cords more than one hepatocyte in thickness. All DEN/control liver sections examined that had hepatocellular carcinomas also had hepatocellular adenomas. Only one mouse in the DEN/MTBE treatment group had a hepatocellular carcinoma and no hepatocellular adenomas. One acidophilic hepatocellular adenoma was found in a DEN/MTBE liver. No acidophilic hepatocellular carcinomas were observed. The effect of MTBE exposure on the mean number of microscopic lesions in all three sections of H&E-stained liver sections at 32 weeks is shown in Figure 3 . In the DEN/control group, 324 microscopic hepatic lesions were identified; 254 (78%) of the hepatic lesions were classified as hepatic foci, 59 (18%) as hepatocellular adenomas, and 11 (3%) as hepatocellular carcinomas. There was no significant difference in the percentage of microscopic lesions classified as hepatic foci (86%), hepatocellular adenomas (10%) or hepatocellular carcinomas (4%) in DEN/MTBE mice as compared to DEN/ control mice. However, the absolute number of microscopic hepatic lesions was 50% less in the DEN/MTBE group (159) as compared to DEN/control mice (324). In the DEN/control group at 32 weeks, there was a mean of 21.2 hepatic foci, 4.9 hepatocellular adenomas and 0.9 hepatocellular carcinomas per liver. In the DEN/MTBE group, there were significant decreases in the mean number of hepatic foci (13.6) and hepatocellular adenomas (1.6), but not hepatocellular carcinomas (0.7) (Figure 3) .
Other hepatic endpoints.
To characterize the lack of tumorpromoting activity of MTBE in spite of its many similarities to the hepatic tumor promoter UG, we evaluated hepatic microsomal cytochrome P450 activity, and non-focal and focal hepatic LI. Induction of hepatic microsomal cytochrome P450 PROD and EROD activity, and focal LI has been associated with UG-induced hepatic tumor-promoting activity. At 16 weeks, MTBE significantly increased PROD and EROD activity in both saline-treated and DEN-initiated mice (Table V) . MTBE increased PROD activity 4.9-and 6.2-fold in salinetreated and DEN-treated mice as compared to their respective controls. Likewise, MTBE increased EROD activity 1.9-and 2.1-fold in saline-treated and DEN-initiated mice.
To determine if MTBE altered hepatocyte proliferation, mice were treated with BrdU via osmotic pumps 3j days prior to necropsy. The non-focal hepatic LI in saline-treated and DEN-initiated mice exposed to MTBE was compared to control mice. Neither MTBE exposure nor DEN initiation had a significant effect on the nonfocal hepatic index at 16 weeks (Table V) . As expected, LI was greatly increased in hepatic 2758 foci relative to normal liver. There was no significant difference in the mean hepatic LI of 33 foci in five randomly chosen DEN/MTBE mice (15.9 ± 4.1) as compared to the focal labeling index in 40 foci in five randomly chosen DEN/control mice (9.8 ± 6.2; Table V) . Consistent with the 16-week stereological and focal LI data (Table IV) , there was no significant difference in the mean number of cells in MTBEexposed foci as compared to DEN/control (Table V) .
Discussion
In their respective chronic bioassays, MTBE and UG exposure increased the incidence of liver tumors, and produced comparable hepatic effects after short-term exposure in female mice ( Table I) . Given these similarities and having previously demonstrated that UG has hepatic tumor-promoting activity in DEN-initiated female mouse liver, we hypothesized that MTBE would also exhibit hepatic tumor-promoting activity in this model system. We found that exposure to MTBE under bioassay conditions for 16 weeks or 32 weeks did not significantly increase the volume fraction of the liver occupied by hepatic foci, mean volume of foci, number of macroscopic lesions or mean number of cells in foci. Under bioassay conditions at the same time point of 16 weeks in this model system, UG increased the volume fraction occupied by foci 3.5-fold, mean size of foci over 6.6-fold, and mean number of macroscopic lesions and cells per focus over 2-fold as compared to DEN/control (9,10). Since increased focal size and liver volume fraction are hallmarks of tumor promotion and since MTBE did not produce these effects, MTBE, unlike UG, did not have hepatic tumor-promoting activity in this experimental model system. MTBE also did not increase the number of hepatic foci per cm 3 or number of foci per liver in DEN-initiated mice or in the absence of DEN treatment. This is consistent with lack of MTBE genotoxicity in in vitro assays (Table I) (12) (13) (14) (15) (16) and supports the lack of initiating activity by MTBE.
Discordance between the tumor-promoting ability of UG and MTBE may be a result of the model system we used. There are many different morphological types of hepatic foci (22, (24) (25) (26) . The biological significance and the cause of the varying phenotypes are unknown (27) . DEN is known to produce a unique spectrum of DNA mutations (28) and predominantly induce basophilic lesions. Tumor promoters clonally expand specific type(s) of genetic lesions (26, 29) , and the number and morphology of liver lesions initiated by DEN in mice are in part dependent upon the subsequent tumorpromoting agent (25) . Although the percentage of acidophilic lesions in MTBE-exposed mice was not greatly increased, die observed increase was consistent at both 16 weeks and 32 weeks. Furthermore, MTBE exposure increased the incidence of mice harboring acidophilic lesions at both time points (Figure 2 ). Thus, MTBE may promote the growth of a subset of initiated cells that DEN does not generally produce. Since no initiators were given in the bioassay in which MTBE increased the incidence of liver rumors, MTBE may have clonally expanded spontaneously initiated cell populations (acidophilic), which may have genetic lesions different from those which DEN generally produces.
In the infant mouse system utilized in this study, the prototypic hepatic tumor promoter phenobarbital produced hepatic neoplastic and non-neoplastic effects similar to those produced by MTBE (30) . Phenobarbital increased liver weight, Twelve-day-old female B6C3F1 mice were initiated with a single i.p. injection of DEN (5 mg DEN/kg, 7.1 ml/kg body weight) or saline. Beginning at 8 weeks of age, groups of 10-12 mice were exposed to 0 or 7986 ± 107 ppm MTBE for 16 weeks. Mean ± SD of 3 microsomal samples c Mean ± SD of 8-9 mice. ''Osmotic pumps containing 16 mg BrdU/ml were implanted 3.5 days before necropsy. At least 1000 non-focal hepatocytes were evaluated in the left lobe. Tviean ± SD of 40 DEN/control foci in five mice and 33 DEN/MTBE foci in five mice. All hepatocytes in individual foci were evaluated. 'Significantly different from appropriate control. Number in parentheses indicates the fold increase relative to appropriate control. induced hepatic microsomal cytochrome P450 content and PROD activity, and produced centrilobular hypertrophy and a transient increase in hepatocyte proliferation (26, 31, 32) . Furthermore, phenobarbital did not significantly increase the mean size of hepatic foci or volume fraction of the liver occupied by hepatic foci and decreased the mean number of adenomas. In DEN-initiated, phenobarbital-treated livers the previously described DEN-induced basophilic lesions predominated (24) , but phenobarbital increased the percentage of acidophilic lesions (26) . Although MTBE was not a hepatic tumor promoter in DEN-initiated female mouse liver, it is quite possible that it may have tumor-promoting activity in other initiation-promotion systems and produce liver tumors through a tumor-promoting mechanism similar to that of phenobarbital.
The absence of tumor-promoting ability in MTBE-exposed mice cannot be the result of an inadequate dosing regimen since the 8000 ppm dose used in this study was marginally toxic, as evidenced by decreased body weight. Caloric restriction and decreased body weight gain have been associated with decreased liver tumor incidence in B6C3F1 mice (33) (34) (35) . Whereas decreased body weight may have contributed to an attenuation in the number of macroscopic lesions, size of hepatic foci and volume fraction of the liver occupied by hepatic foci in MTBE-exposed mice, body weight decreases of approximately 25% did not inhibit the detection of a liver tumor response in the cancer bioassay (6) .
In spite of the general similarities in short-term effects and liver tumor responses in CD-I and B6C3F1 mice (36) , MTBE may only exhibit liver tumorigenesis in the CD-I mouse. Although this is improbable and lacks a known scientific basis, it cannot definitely be ruled out. However, our hypothesis was that MTBE is hepatocarcinogenic by a mechanism similar to that of UG. We clearly demonstrated that MTBE does not have tumor-promoting ability in the same experimental model system in which UG has tumor-promoting ability.
Hepatomegaly, transient increase in hepatocyte proliferation in the absence of hepatocyte toxicity (mitogenicity), and induction of hepatic microsomal cytochrome P450 activity were short-term and subchronic effects correlated with the tumor-promoting ability of UG, and we believed would be predictive of MTBE tumor-promoting ability. MTBE and UG produced increases in liver weight, hepatocyte proliferation and P450 induction that were quantitatively, as well as qualitatively similar (11). However, MTBE and UG differed in their hepatic tumor-promoting activity. Virtually all xenobiotics with hepatic tumor-promoting activity increase liver weight and induce hepatocyte proliferation. However, many chemicals that did not have tumor-promoting activity also produce these effects (37) . A correlation has been observed between the degree of G J.Moser el al induction of PROD and tumor-promoting activity (38) . Thus, lack of tumor-promoting ability of MTBE could be due to the relatively subtle induction of cytochrome P450 enzymes. However, MTBE produced an increase in activity very similar to that produced by UG (9) . Our data support that not only individually, but together, hepatomegaly, transient increase in hepatocyte proliferation in the absence of hepatocyte toxicity, and induction of hepatic microsomal cytochrome P450 activity are not specific and sufficient for tumor promotion in the mouse liver.
If the short-term tests utilized are not relevant to hepatic tumor-promoting ability, the importance of the similar acute responses we saw in the CD-I and B6C3F1 mice may be negated. On the other hand, the discordance between shortterm effects and tumor-promoting activity may be due to the difference in hepatic LI at 21 days in CD-I and B6C3F1 mice. LI in MTBE-exposed B6C3F1 mice was decreased, while LI in MTBE-exposed CD-I mice was increased as compared to their respective controls. These differences are likely due to changes in the control values for CD-I and B6C3F1 mice. The increase in LI in CD-I mice at 21 days suggested that the increase in hepatic DNA synthesis after MTBE exposure may have been sustained. However, others have demonstrated that MTBE transiently increased the hepatic LI in female CD-1 mice at 5 days, while hepatic LI was not significantly different from controls at 28 and 52 days (40). Given that the hepatic LI in female mouse liver is highly variable (21) , the significance of the slight increase in LI at 21 days in CD-I mice is unknown.
A decrease in the number of macroscopic lesions relative to control liver without a decrease in number of foci per cm 3 and liver suggests that MTBE does not inhibit focus formation or cause regression to nondemonstrable lesions. Rather, MTBE decreases the growth of DEN-initiated lesions. Although the number of foci and foci size in the present study did not allow a definitive determination of death rate, mathematical modeling (41) is being used to elucidate focal cell proliferation and cell death in DEN/control and DEN/MTBE lesions.
The belief that hepatocellular adenomas and carcinomas arise from hepatic foci is supported by similar phenotypes of foci, and hepatocellular adenomas and carcinomas, their time of appearance, and the observance of tumors arising in hepatic foci. Over 98% of foci in DEN/control and 90% of foci in DEN/MTBE mice were of the basophilic phenotype, and all except one of the hepatocellular adenomas and carcinomas identified microscopically were of the basophilic phenotype. Even though MTBE significantly decreased the size of hepatic lesions, a subpopulation of foci was able to progress to hepatocellular carcinomas. This suggests that there may be at least two populations of basophilic DEN-initiated hepatocytes. MTBE may inhibit one population of basophilic hepatocytes, while allowing a different population to grow and progress to hepatocellular carcinomas.
We determined the ratio between the number of foci per liver and the number of macroscopic lesions per liver at 32 weeks (Table IV, Figure 2) . A significant difference in the mean ratio was observed between DEN/control and DEN/ MTBE mice (P < 0.002). In DEN/control livers one macroscopic lesion emerged for every 25 foci, while in DEN/MTBE livers one macroscopic lesion arose for every 63 foci. These data are consistent with what we found microscopically; there were approximately three times more hepatocellular adenomas and carcinomas in DEN/control as in DEN/MTBE livers. The high conversion of foci to macroscopic lesions in mice is unique as compared with rats. Kaufman et al. (42) derived a ratio of 11 000 foci for each liver neoplasm in methyl(acetoxymethyl)nitrosamine (DMN-AC)-initiated rats and a ratio of 1600 in DMN-AC livers promoted with phenobarbital. Whereas initiators and promoters can alter the ratios, our data confirm that mice are an order of magnitude more efficient than rats at converting hepatic foci to neoplasms. Although the basis for this conversion remains unknown, the increased efficiency may contribute to an increased incidence of tumors in mouse liver as the most common positive endpoint in chronic bioassays and warrants further study.
MTBE is representative of a number of structurally similar oxygenated compounds such as ethyl tertiary butyl ether and tertiary amyl methyl ether that may have responses similar to those produced by MTBE. An improved understanding of MTBE-induced hepatocarcinogenicity and toxicity may have important health risk implications not only for MTBE and related agents, but ultimately for those formulations of UG supplemented with MTBE and other oxygenates.
